top of page

Our expertise

The AMR Think-Do-Tank, Geneva International brings together experts and professionals from all backgrounds, in Human and animal medicine, environmental issues, political economy, and anthropology, and from all levels: academia, health care workers and cleaners groups, as well as users, patients, of health systems, so as to engage in advocacy and to propose any necessary studies and actions to the public authorities, to concerned professionals, stakeholders or the general public, and notably to the UN and to 'International Geneva'.


AMR Think-do-Tank is registered as an Association

(equivalent 501 C3 in the USA) under Swiss law. 


The AMR Think-Do-Tank brings expertise for the achievements of all features of the Global Action Plan on AMR (GAPAMR):

- Government engagements and national action plans

- Stewardship, advocacy: public and decision-makers
- Infection prevention and control (IPC) and outbreaks investigations whenever there are suspect cases
- "One Health" FAO, WHO, OIE Human, animal health and the environment.
- Importance of the Environment in AMR rise/spread

- Water and Waste management (WASH Water-Sanitation-Hygiene UN Resolution) and impacts of Climate – Extreme Weather Events on WASH systems, water, wastes, animal waste, health centers.
- Surveillance and Monitoring
- Diagnostics and vaccines
- R&D, intellectual property and innovation
- Economic impact and investments
- E-Health and ambulatory health delivery systems
- Strengthening national health systems in view of the International Health Regulations (IHR) and the UN adopted Universal Health Coverage (UHC/SDGs)
- The issue of Risk management and Global Health Security

To achieve the above, the AMR Think-Do-Tank, Geneva International bring an international panel of experts who may conduct intelligence watch, analysis, and databases bearing on:

a) new technologies, inventions, discoveries, in fundamental, applied and implementation research
, of use in mastering antimicrobial resistance (AMR) and its spread.

b) innovations to protect health systems and patients from AMR infections, such as the development of new architectures, ambulatory care, new health systems (as for example, the Swiss support for the assessment of space research derived discoveries of use in public health, with WHO)

c) innovations in treatments of human and animal infectious diseases, such as immunotherapies, bacteriophages, plants, or products derived from plants used in traditional medicines (as proven effective by adequate scientific studies), and others...

d) innovation in diagnostic tools, their use and means of deployment, notably in developing country settings.

e) innovations in vaccines, in the development of vaccination programs, and the search for new vaccines, while taking safety into consideration (moving away from multiple use vials, in LMIC where injection safety practices is not guarantied, doing reporting data on side effects, or adjuvants).

f) innovations and projects in implementation research on Patient Safety, by and for Patients, (PfPS), Community safety, by and for communities.

- through the promotion of hygiene, safe injection, and basic understanding of AMR pathogens spread and transmission, and IPC with simple tools and visuals (including pictograms, eventually comic books).

- through use of PDCA (Plan Do Check Act- or Demings' circle, a systems-based approach) to strengthen team learning and implementation of Infection Prevention and Control (IPC) in hospital/health care settings.

g) PfPS: more generally, to collect intelligence watch so as to monitor and initiate smart approaches to
diminish and correct errors in health care in relation to AMR
. Establish the collect of data/stories on unsafe care on an anonymous basis, since “denunciations” place both a patient and a health care worker at risk. The point being not to punish, but to re-examine the system to decrease risks of errors. (Outcome of Dakar, Senegal PfPS seminar).


h) R&D and setting up of innovative systems in the process of waste management of concern to AMR:
hospital waste, industrial animal production (farming, slaughterhouses, and pharmaceutical wastes), as well as municipal wastewaters, and relevant infrastructure. Research and promotion of methods for IPC in industrial animal production (technologies and methods).

I) watch on issues relative to racial or “Gender” discrimination in health, identifying discriminatory ‘health’ discourses & approaches towards women in general, or racial and ethnic groups, or towards youth, the elderly, or persons living with a disability.


g) innovations in works of other disciplines: anthropology, social sciences, architecture, ecology, and political economy or ethics, having an impact on the possibility of mastering the AMR phenomena.

bottom of page